DE69307705D1 - Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung - Google Patents

Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung

Info

Publication number
DE69307705D1
DE69307705D1 DE69307705T DE69307705T DE69307705D1 DE 69307705 D1 DE69307705 D1 DE 69307705D1 DE 69307705 T DE69307705 T DE 69307705T DE 69307705 T DE69307705 T DE 69307705T DE 69307705 D1 DE69307705 D1 DE 69307705D1
Authority
DE
Germany
Prior art keywords
tolerance
pct
dichlorophenyl
diamino
triazinisethionate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69307705T
Other languages
English (en)
Other versions
DE69307705T2 (de
Inventor
Meire Nakamura-Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929212495A external-priority patent/GB9212495D0/en
Priority claimed from GB939308654A external-priority patent/GB9308654D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69307705D1 publication Critical patent/DE69307705D1/de
Publication of DE69307705T2 publication Critical patent/DE69307705T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69307705T 1992-06-12 1993-06-11 Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung Expired - Fee Related DE69307705T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929212495A GB9212495D0 (de) 1992-06-12 1992-06-12
GB939308654A GB9308654D0 (en) 1993-04-27 1993-04-27 Therapeutic triazine compounds and use
PCT/GB1993/001243 WO1993025207A1 (en) 1992-06-12 1993-06-11 Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs

Publications (2)

Publication Number Publication Date
DE69307705D1 true DE69307705D1 (de) 1997-03-06
DE69307705T2 DE69307705T2 (de) 1997-05-22

Family

ID=26301060

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69307705T Expired - Fee Related DE69307705T2 (de) 1992-06-12 1993-06-11 Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung

Country Status (23)

Country Link
US (1) US5801171A (de)
EP (1) EP0644763B1 (de)
JP (1) JP3439211B2 (de)
KR (1) KR100268823B1 (de)
AT (1) ATE147980T1 (de)
AU (1) AU688729B2 (de)
CA (1) CA2137782A1 (de)
CZ (1) CZ284061B6 (de)
DE (1) DE69307705T2 (de)
DK (1) DK0644763T3 (de)
ES (1) ES2097516T3 (de)
GB (1) GB2282326A (de)
GR (1) GR3022671T3 (de)
HR (1) HRP930964B1 (de)
IL (1) IL105986A (de)
MY (1) MY109330A (de)
NO (1) NO306451B1 (de)
NZ (1) NZ253260A (de)
SI (1) SI9300318A (de)
SK (1) SK279730B6 (de)
TW (1) TW284689B (de)
WO (1) WO1993025207A1 (de)
YU (1) YU48573B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU530999B2 (en) * 1979-06-01 1983-08-04 Wellcome Foundation Limited, The Substituted amino triazines and their use in treatment of cns disorders
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds

Also Published As

Publication number Publication date
CA2137782A1 (en) 1993-12-23
MY109330A (en) 1997-01-31
KR100268823B1 (ko) 2000-12-01
IL105986A (en) 1998-12-06
HRP930964A2 (en) 1996-02-29
YU41093A (sh) 1996-10-09
ES2097516T3 (es) 1997-04-01
JP3439211B2 (ja) 2003-08-25
SK279730B6 (sk) 1999-02-11
EP0644763A1 (de) 1995-03-29
TW284689B (de) 1996-09-01
SI9300318A (en) 1994-03-31
NO944790L (no) 1994-12-09
GR3022671T3 (en) 1997-05-31
CZ284061B6 (cs) 1998-08-12
NZ253260A (en) 1997-05-26
SK153494A3 (en) 1996-01-10
GB2282326A (en) 1995-04-05
DE69307705T2 (de) 1997-05-22
DK0644763T3 (da) 1997-07-28
ATE147980T1 (de) 1997-02-15
EP0644763B1 (de) 1997-01-22
AU4345293A (en) 1994-01-04
KR950701814A (ko) 1995-05-17
AU688729B2 (en) 1998-03-19
YU48573B (sh) 1998-12-23
JPH07507790A (ja) 1995-08-31
GB9423697D0 (en) 1995-01-11
CZ312894A3 (en) 1995-07-12
NO944790D0 (no) 1994-12-09
WO1993025207A1 (en) 1993-12-23
HRP930964B1 (en) 2000-06-30
IL105986A0 (en) 1993-10-20
US5801171A (en) 1998-09-01
NO306451B1 (no) 1999-11-08

Similar Documents

Publication Publication Date Title
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
BR9306361A (pt) Agentes para o tratamento de desordens resultantes do abuso de substâncias
DE69307705D1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
ATE204476T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
GR3033061T3 (en) Use of benzonaphthalene derivatives to make medicaments for treating diseases of the central nervous system
SE9503476D0 (sv) New combination

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee